About Karius
Karius is revolutionizing infectious disease diagnostics through advanced metagenomic sequencing technology. The company leverages the power of clinical metagenomics to detect microbial cell-free DNA (mcfDNA) circulating throughout the body from pathogens that may cause infections. Their vision is to create a world where every patient gets a clear and timely diagnosis. Karius offers two primary diagnostic products: Karius Spectrum, a blood test that detects over 1,000 fungi, bacteria, DNA viruses, and parasites associated with deep-seated and difficult-to-diagnose systemic infections; and Karius Focus | BAL, a bronchoalveolar lavage fluid-based test designed for detection of over 500 pathogens associated with lung infections. Both tests are powered by the Karius Helion platform, which combines proprietary chemistry, a continuously updated clinical-grade database of over 20,000 microbial references, and advanced machine learning algorithms. The company serves healthcare providers treating high-risk hospitalized patients, particularly immunocompromised individuals facing pneumonia, febrile neutropenia, invasive fungal infections, endocarditis, and fever of unknown origin. Karius provides results typically within one day after sample receipt, compared to conventional methods that can take days to weeks. The company's CLIA-certified and CAP-accredited laboratory is based in Redwood City, California, and they have established partnerships with leading institutions including Mayo Clinic Laboratories to expand access to their diagnostic solutions.
Mission & Story
Mission
By leveraging the power of clinical metagenomics, our vision is to create a world where every patient gets a clear and timely diagnosis.
Clinical Focus
Medical conditions and clinical areas addressed by Karius.
Who It Serves
Milestones & Awards
Recent Milestones
Launched Karius Focus | BAL metagenomic test for lung infections in 2025. Announced collaboration with Mayo Clinic Laboratories to expand access to metagenomic infectious disease diagnostics.
Awards & Recognition
Named one of The Top 25 Biotech and Life Sciences Companies of 2025. Recognized as a 2025 Top Workplace by the San Francisco Chronicle for two consecutive years.
Key Partnerships
Company Details
- Headquarters
- Redwood City, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
AIxMed
AIxMed develops AI-powered computational cytology platforms for cancer detection and diagnosis. The company's flagship product AIxURO analyzes urine cytology for bladder cancer, with additional platforms in development for thyroid, cervical, and lung cancer screening.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.